Neuralink's 1,024-electrode brain-link bet: first human in 2024, UK trial by 2026

Neuralink develops the N1, a coin-sized wireless brain implant that records neural signals through 1,024 electrodes on 64 ultra-thin threads, inserted by its R1 surgical robot, to let people with paralysis control computers, phones and assistive devices with thought.

A wireless robot-implanted link with 1,024 electrodes gives paralyzed people real computer control, and once that works the same platform scales to other senses.

Neuralink was founded in 2016 by Elon Musk with a team of scientists and engineers, on the mission of building a generalized brain interface that restores autonomy to people with unmet medical needs. Instead of adapting electrodes used in labs, the company designed from scratch the N1 — a coin-sized implant with 1,024 electrodes spread across 64 threads finer than a human hair, inserted by a purpose-built R1 robot — and pursued FDA approval to test it in humans. Noland Arbaugh, paralyzed from the shoulders down since a 2016 accident, became the first human participant in January 2024.

In March 2024 Neuralink livestreamed Arbaugh moving a computer cursor by thought; he described the control as intuitive and said he used the device for reading, language apps and chess. In May 2024, ABC News reported that some threads had retracted after surgery, sharply cutting usable electrodes and nearly leading to device removal; Neuralink said it restored and improved his performance through a more sensitive recording algorithm, better signal translation and UI changes. In August 2024, Musk said a second patient with a spinal-cord injury had received the implant, with about 400 of its 1,024 electrodes working, and that eight more implants were planned that year as part of clinical trials.

The clean-sheet design — coin-sized, wireless, 1,024 electrodes on 64 robot-inserted threads — aimed at a higher bandwidth ceiling than earlier clinical BCIs.

A first product aimed at restoring digital independence for paralyzed people created a real, urgent customer before any consumer market existed.

When the first patient's threads retracted, engineering fixes restored and improved control, showing the platform could absorb real-world failure.

Regulatory momentum — FDA approval for the first US trial, then an MHRA-approved UK study with seven surgeries in late 2025 — kept the platform expanding across countries.

Keep the goal fixed while the tech iterates: when threads retracted in patient one, Neuralink treated it as an engineering fix, not a verdict — the tolerance for hard hardware problems is the moat.

As of September 2026, the N1 remains an investigational device in early-feasibility trials rather than a commercial product. UCLH's National Hospital for Neurology and Neurosurgery, the UK's first site, reported on 2026-01-29 that seven patients had been implanted between October and December 2025 under the GB-PRIME study, following earlier clinical trials in the United States and Canada; patients there and abroad use the implant to control computers, smartphones and robotic arms. Neuralink continues iterating on the platform and its surgical robot toward a marketable device.